Abstract
Vicriviroc is an investigational CCR5 inhibitor that seemed promising in industry-funded, phase I clinical trials involving treatment-naive HIV-infected patients. However, recent results from a phase II trial of this drug (also industry funded) are less encouraging. A total of 92 treatment-naive patients with CCR5-tropic virus only were randomized to receive double-blinded, once-daily vicriviroc (25 mg, 50 mg, or 75 mg) or placebo for 14 days, followed by combination therapy with either vicriviroc or open-label efavirenz, each with AZT/3TC, for …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
